31 July 2021>: Clinical Research
Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy
Xingqin Zhou 1BCE , Yazhou Chang 2BD , Jing Qian 1BF , Chaoyan Shen 1DEF , Jie Han 1EF , Hongyu Zhao 1DF , Renan Chang 3AG*DOI: 10.12659/MSM.929474
Med Sci Monit 2021; 27:e929474
Table 4 Dose adjustment strategy of fluorouracil based on the AUC.
Gamelin, 2008 [11] | Wasif, 2009 [12] | Kaldate, 2012 [13] | Wilhelm, 201614 | Denda, 201615 | |||||
---|---|---|---|---|---|---|---|---|---|
AUC | Adjustment range (%) | AUC | Adjustment range (%) | AUC | Adjustment range (%) | AUC | Adjustment range (%) | AUC | Adjustment range (%) |
70 | 150 | 30 | Repeat the original dose; if the AUC is | 30 | |||||
4–8 | 50 | 5–10 | 100 | 8–13 | 24 | 8–13 | 25 | 8–13 | 25 |
8–10 | 40 | 10–15 | 25 | 14–16 | 18 | 14–16 | 20 | 14–16 | 20 |
10–12 | 30 | 15–20 | 15 | 17–19 | 12 | 17–19 | 10 | 17–19 | 10 |
12–15 | 20 | 20–25 | 0 | 20–30 | 0 | 20–29 | 0 | 20–30 | 0 |
15–18 | 10 | 25–30 | −10 | 30–33 | −12 | 30–33 | −10 | 30–33 | −10 |
18–20 | 5 | 30–35 | −15 | 34–36 | −18 | 34–36 | −20 | 34–36 | −20 |
20–24 | 0 | 35–40 | −20 | 37–39 | −24 | 37–39 | −25 | 37–39 | −25 |
24–48 | −5 | – | – | ≥40 | −30 | ≥40 | −30 | ≥40 | −30 |
28–31 | −10 | – | – | – | – | – | – | – | – |
>31 | −15 | – | – | – | – | – | – | – | – |